<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02067143</url>
  </required_header>
  <id_info>
    <org_study_id>LAL1913</org_study_id>
    <nct_id>NCT02067143</nct_id>
  </id_info>
  <brief_title>MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate</brief_title>
  <acronym>LAL1913</acronym>
  <official_title>National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in different centres and will study adult patients with
      Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study
      treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase
      (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the
      achievement of an early negative minimal residual disease (MRD) status. The MRD study
      supports a risk/MRD-oriented final consolidation phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this clinical study in adult ALL is to improve , by risk category, the overall
      disease-free survival in relation to the achievement of an early MRD negative status and
      following induction/consolidation with Peg-ASP, lineage-targeted methotrexate infusions and
      other disease-specific therapeutic elements, with or without the application of allogeneic or
      autologous SCT depending on risk class and MRD study results. A survey of severe infections
      occurring along the entire chemotherapy and stem cell transplant program and until 2 years
      from the achievement of CR will be performed with the aim to increase the knowledge of these
      complications and to evaluate their impact on the antileukemic program and on the long term
      outcome of the underlying malignancy. The prospective survey of severe infections will be
      performed as an ancillary observational objective of the present study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">October 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients on disease free survival (DFS).</measure>
    <time_frame>At two years.</time_frame>
    <description>DFS is defined as the time interval between the evaluation of CR and relapse of the disease or death in first Complete Response (CR); patients still alive, in first CR, will be censored at the time of the last follow-up. In this case, the DFS will be truncated at 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patients in complete remission (CR).</measure>
    <time_frame>After approximately two months from start of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of early bone marrow MRD negativity.</measure>
    <time_frame>At 4 timepoints (week 4, 10, 16 22).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early bone marrow MRD response (&lt;10-4).</measure>
    <time_frame>At 4 weeks following induction cycle 1 with Peg-ASP.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) estimation.</measure>
    <time_frame>At two years from diagnosis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Relapse (CIR) estimation.</measure>
    <time_frame>At two years from CR achievement.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients dead due Treatment-related mortality (TRM).</measure>
    <time_frame>By the end of the study (4.5 years from first centre opened).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite DFS, OS, CIR.</measure>
    <time_frame>At two years from CR achievement and rate of TRM in LL patients.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Minimal Residual Disease (MRD) monitoring.</measure>
    <time_frame>During treatment at time point 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Infections (SI) during treatment.</measure>
    <time_frame>At the end of the study (4.5 years from first centre opened).</time_frame>
    <description>Description: Number and type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events (AE).</measure>
    <time_frame>By the end of the study (4.5 years from first centre opened)</time_frame>
    <description>Excluding SI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite evaluation of impact of age (≤55 and &gt;55) and risk category group (SR, HR, VHR - as defined) on outcomes: DFS, CIR.</measure>
    <time_frame>At two years for CR achievement, OS at two years from diagnosis and TRM.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Untreated Philadelphia Positive Acute Lymphoblastic Leukemia</condition>
  <condition>De Novo</condition>
  <condition>Secondary</condition>
  <condition>Low-dose Corticosteroids Pretreatment</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prephase PDN + CY</intervention_name>
    <arm_group_label>Study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 1 Induction</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>VCR + IDR + DXM + ASP + IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 2 Induction / Early consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>IDR + CY + ARA-C + ASP + 6MP + DXM + IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 3 Early consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>MTX + ARA-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 4 Consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>VCR + IDR + CY + ARA-C + 6-MP + DXM + IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 5 Consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>MTX + ASP + 6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 6 Consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>VCR + IDR + CY + ARA-C + ASP + 6MP + DXM + IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 7 Consolidation</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>MTX + ARA-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycle 8 Reinduction</intervention_name>
    <arm_group_label>Study population</arm_group_label>
    <other_name>VCR + IDR + DXM + PDN + CY + IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance</intervention_name>
    <description>If MRD negative MRD u/k SR</description>
    <arm_group_label>Study population</arm_group_label>
    <other_name>CY or VP and 6MP/MTX + 12 cycles of 6MP/MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic SCT or Autologous SCT</intervention_name>
    <description>If MRD positive MRD u/k HR</description>
    <arm_group_label>Study population</arm_group_label>
    <other_name>+ Maintenance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent according to ICH/EU/GCP and national local laws.

          -  Age 18-65 years.

          -  A diagnosis of untreated Ph- ALL or LL is required, either de novo or secondary to
             chemo-radiotherapy for other cancer. Pretreatment with low-dose corticosteroids in
             patients presenting with hyperleukocytosis is allowed. All diagnostic procedures need
             to be performed on freshly obtained bone marrow (BM) and peripheral blood (PB)
             samples. The diagnosis must be one of: de novo ALL, secondary ALL, B-/T-cell LL Full
             cytological, cytochemical, cytogenetic and immunobiological disease characterization
             according to EGIL and WHO classifications. Bone marrow and peripheral blood sampling
             (ALL) or biopsy specimen (LL) are required for MRD study. Detailed indications on
             patient registration, storage of representative diagnostic material and diagnostic
             work-up, including the forwarding of samples for MRD study are given in Appendix B.

          -  Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) for MRD study.

          -  ECOG performance status 0-2, unless a performance of 3 is unequivocally caused by the
             disease itself and not by preexisting comorbidity, and is considered and/or documented
             to be reversible following the application of antileukemic therapy and appropriate
             supportive measures.

        Exclusion Criteria:

          -  Diagnosis of Burkitt's leukemia or lymphoma.

          -  Down's syndrome

          -  Pre-existing, uncontrolled pathology such as heart failure (congestive/ischemic, acute
             myocardial infarction within the past 3 months, untreatable arrhythmias, NYHA classes
             III and IV), severe liver disease with serum bilirubin &gt;3 mg/dL and/or ALT &gt;3 x upper
             normal limit (unless attributable to ALL), kidney function impairment with serum
             creatinine &gt;2 mg/dL (unless attributable to ALL), and severe neuropsychiatric disorder
             that impairs the patient's ability to understand and sign the informed consent, or to
             cope with the intended treatment plan. N.B. For altered liver and kidney function
             tests, eligibility criteria can be reassessed at 24-96 hours, following the
             institution of adequate supportive measures.

          -  Pre-existing HIV positive serology (i.e. already known before enrolment). If HIV
             positivity is detected after enrolment, the patient is sent off study.

          -  A history of cancer that is not in a remission phase following surgery and/or
             radiotherapy and/or chemotherapy, with life expectancy &lt;1 year.

          -  Pregnancy declared by the patient herself, unless a decision is taken with the patient
             to induce a therapeutic abortion in order to carry on with ALL therapy. A pregnancy
             test is performed at diagnosis but does not preclude the enrolment into study. Fertile
             patients will be advised to adopt contraceptive methods while on treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Bassan, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda ULSS 12 Veneziana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Foà, Pr.</last_name>
    <role>Study Director</role>
    <affiliation>Policlinico Umberto I, Hematology Department.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az.Ospedaliera S.G.Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprensorio Sanitario di Bolzano - Azienda Sanitaria dell'Alto Adige - Ematologia e Centro TMO - Ospedale S.Maurizio</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTMO - Ematologia - Ospedale &quot;Binaghi&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Onco-Ematologia - A.O. S.Anna e S.Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Cona (Ferrara)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia C.T.M.O. Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia ASO S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST.Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot; P.O. Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia- Ospedale dell'Angelo - Mestre</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. CTMO Ematologia - Osp. S.Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Day Hospital dell'U.O.C di Ematologia e CTMO Padiglione 1 TORRE DELLE MEDICINE, 6° piano</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia Cancer Center Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC di Ematologia e Trapianti di Cellule Staminali Emopoietiche - AOU San Giovanni di Dio e Ruggi D'Aragona</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.L.S.S. 9 UOC Ematologia - Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Untreated philadelphia positive acute lymphoblastic leukemia</keyword>
  <keyword>De novo</keyword>
  <keyword>Secondary</keyword>
  <keyword>Low-dose corticosteroids pretreatment</keyword>
  <keyword>Pegylated asparaginase</keyword>
  <keyword>Lineage-targeted risk and minimal residual disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

